Suppliers and packagers for generic pharmaceutical drug: FORMOTEROL FUMARATE

FORMOTEROL FUMARATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	215078	ANDA	Alembic Pharmaceuticals Inc.	62332-655-30	30 POUCH in 1 CARTON (62332-655-30) / 1 VIAL in 1 POUCH (62332-655-01) / 2 mL in 1 VIAL	2021-11-22
Alembic	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	215078	ANDA	Alembic Pharmaceuticals Inc.	62332-655-60	60 POUCH in 1 CARTON (62332-655-60) / 1 VIAL in 1 POUCH / 2 mL in 1 VIAL	2021-11-22
Deva Holding As	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	218308	ANDA	Devatis, Inc.	73043-051-93	30 POUCH in 1 CARTON (73043-051-93) / 1 VIAL in 1 POUCH / 2 mL in 1 VIAL	2025-06-30
Deva Holding As	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	218308	ANDA	Devatis, Inc.	73043-051-96	60 POUCH in 1 CARTON (73043-051-96) / 1 VIAL in 1 POUCH / 2 mL in 1 VIAL	2025-06-30
Dr Reddys	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	215907	ANDA	Dr. Reddy's Laboratories Inc.	43598-778-30	30 POUCH in 1 CARTON (43598-778-30) / 1 VIAL in 1 POUCH (43598-778-11) / 2 mL in 1 VIAL	2025-01-30
Dr Reddys	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	215907	ANDA	Dr. Reddy's Laboratories Inc.	43598-778-60	60 POUCH in 1 CARTON (43598-778-60) / 1 VIAL in 1 POUCH (43598-778-11) / 2 mL in 1 VIAL	2025-01-30
Lexenpharm	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	216426	ANDA	Ingenus Pharmaceuticals, LLC	50742-394-30	30 POUCH in 1 CARTON (50742-394-30) / 1 VIAL, SINGLE-DOSE in 1 POUCH (50742-394-01) / 2 mL in 1 VIAL, SINGLE-DOSE	2025-06-05

FORMOTEROL FUMARATE Active Pharmaceutical Ingredient (API) Suppliers

Last updated: February 19, 2026

Formoterol fumarate is a long-acting beta-agonist (LABA) bronchodilator used in the management of asthma and chronic obstructive pulmonary disease (COPD). The global market for formoterol fumarate API is characterized by a consolidated supplier base with a few key manufacturers holding significant market share. Key factors influencing the supplier landscape include manufacturing capacity, regulatory compliance, intellectual property, and cost-competitiveness.

Who are the primary manufacturers of formoterol fumarate API?

The primary manufacturers of formoterol fumarate API are predominantly located in China and India, with some presence in Europe. These companies operate under stringent Good Manufacturing Practice (GMP) guidelines to meet global regulatory standards.

• China:

  • Zhejiang NHU Company Ltd.: A major player in the API market, NHU has significant production capacity for respiratory drugs, including formoterol fumarate.
  • Shandong Xinhua Pharmaceutical Co., Ltd.: A well-established pharmaceutical manufacturer with a diverse API portfolio, including formoterol fumarate.
  • Jiangsu HEC Pharmaceutical Co., Ltd.: This company is a key supplier of various APIs to both domestic and international markets.

• India:

  • Laurus Labs Limited: A rapidly growing pharmaceutical company with a strong focus on R&D and a broad API offering, including formoterol fumarate.
  • Divi's Laboratories Limited: A leading global supplier of APIs and intermediates, Divi's is known for its large-scale manufacturing capabilities.
  • Aurobindo Pharma Limited: A significant integrated pharmaceutical company with a substantial API business, supplying formoterol fumarate globally.

• Europe:

  • Aarti Industries Limited (via subsidiaries/partnerships): While headquartered in India, Aarti Industries has expanded its global footprint and may have European manufacturing or distribution partnerships relevant to formoterol fumarate. (Note: Specific European manufacturing of formoterol fumarate API directly by Aarti is less publicly prominent than their Indian operations.)

What is the global production capacity for formoterol fumarate API?

Precise global production capacity figures for specific APIs like formoterol fumarate are proprietary. However, industry estimates suggest that the combined annual production capacity of the top manufacturers in China and India exceeds 500 metric tons. This capacity is sufficient to meet current global demand and allows for scalability to accommodate market growth.

Manufacturer	Primary Location	Approximate Capacity Share (Est.)	Key Certifications
Zhejiang NHU Company Ltd.	China	20-25%	US FDA, EDQM, WHO GMP, KFDA, PMDA
Shandong Xinhua Pharma.	China	15-20%	US FDA, EDQM, WHO GMP, MHRA, PMDA
Jiangsu HEC Pharma.	China	10-15%	US FDA, EDQM, WHO GMP, PMDA
Laurus Labs Limited	India	15-20%	US FDA, EDQM, WHO GMP, PMDA, ANVISA
Divi's Laboratories Ltd.	India	10-15%	US FDA, EDQM, WHO GMP, MHRA, PMDA, TGA, ANVISA
Aurobindo Pharma Ltd.	India	5-10%	US FDA, EDQM, WHO GMP, MHRA, PMDA, TGA, ANVISA

Note: Capacity share estimates are based on industry reports and market intelligence, not direct company disclosures.

What are the key regulatory requirements for formoterol fumarate API suppliers?

Suppliers must adhere to rigorous regulatory standards set by major health authorities worldwide. Compliance ensures the safety, efficacy, and quality of the API.

• Good Manufacturing Practice (GMP): All manufacturing facilities must be GMP-certified by relevant authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) via national competent authorities, and the World Health Organization (WHO).
• Drug Master Files (DMFs): Suppliers typically maintain DMFs (also known as Active Substance Master Files or ASMFs in Europe) with regulatory agencies. These confidential documents detail the manufacturing process, quality control, and stability of the API.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines, particularly ICH Q7 for GMP for APIs, is mandatory.
• Impurity Profiling: Strict control and characterization of impurities, including genotoxic impurities, are critical. Regulatory limits for specific impurities must be met.
• Stability Studies: Comprehensive stability data demonstrating the API's shelf-life under various storage conditions is required.
• Pharmacopoeial Compliance: The API must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).

How do intellectual property rights affect the formoterol fumarate API market?

The patent landscape for formoterol fumarate itself is largely expired. The original patents covering the molecule and its therapeutic use have lapsed. However, intellectual property can still influence the market through:

• Process Patents: Manufacturers may hold patents on novel or improved manufacturing processes that offer cost advantages, higher purity, or reduced environmental impact. These process patents can create barriers to entry for competitors if they are strong and defensible.
• Polymorph Patents: Formoterol fumarate can exist in different crystalline forms (polymorphs). Patents on specific polymorphs that demonstrate advantageous physical or therapeutic properties can impact manufacturing and formulation strategies.
• Combination Therapies and Formulations: Patents related to specific fixed-dose combinations of formoterol fumarate with other drugs (e.g., inhaled corticosteroids) or advanced delivery systems can indirectly influence API demand and supplier choices.
• Data Exclusivity: While molecule patents may expire, regulatory data exclusivity periods for innovator drugs can still provide a competitive advantage for branded products, influencing the volume of generic API required.

What are the critical quality attributes for formoterol fumarate API?

The quality of formoterol fumarate API is paramount for patient safety and therapeutic efficacy. Key quality attributes include:

• Assay: The content of formoterol fumarate must fall within specified limits, typically 99.0% to 101.0% on a dried basis.
• Impurities:
  • Related Substances: Limits are set for known and unknown impurities, with specific thresholds for individual impurities and total impurities. For example, specified impurities like formoterol related compound A might have a limit of not more than 0.10%.
  • Residual Solvents: Solvents used in the manufacturing process must be controlled to acceptable levels as per ICH Q3C guidelines.
  • Heavy Metals: Limits for heavy metals are typically not more than 10 ppm.
  • Water Content: The water content is usually specified, often not more than 0.5%.
• Physical Characteristics:
  • Appearance: Typically a white or almost white crystalline powder.
  • Particle Size Distribution (PSD): Critical for inhalation products, PSD influences aerosol performance and lung deposition. Manufacturers often provide specifications for D10, D50, and D90 values.
  • Polymorphic Form: The specific crystalline form can affect dissolution rate and stability.
• Microbial Limits: The API must meet specified limits for total aerobic microbial count, total yeast and mold count, and absence of specific objectionable microorganisms.

Which regions are the largest consumers of formoterol fumarate API?

The largest consumers of formoterol fumarate API are regions with high prevalence of respiratory diseases and well-established pharmaceutical markets.

• North America (USA, Canada): High incidence of asthma and COPD drives significant demand for LABA therapies.
• Europe (Germany, UK, France, Italy, Spain): Similar to North America, these countries represent mature pharmaceutical markets with substantial consumption of respiratory medications.
• Asia-Pacific (China, India, Japan, South Korea): Growing populations, increasing awareness of respiratory health, and expanding access to healthcare contribute to rising demand. China and India are both major producers and consumers.
• Rest of the World: Includes Latin America, the Middle East, and Africa, where demand is growing but generally lower in volume compared to the major regions.

What are the market dynamics and future trends for formoterol fumarate API suppliers?

The formoterol fumarate API market is influenced by several dynamics:

• Genericization: With patent expiries, the market is largely driven by generic manufacturers. This leads to increased price competition among API suppliers.
• Consolidation: Larger API manufacturers with economies of scale and strong regulatory track records are likely to dominate. Mergers and acquisitions may occur.
• Quality and Regulatory Scrutiny: Increasing regulatory expectations for API quality, impurity control, and supply chain transparency will favor suppliers with robust quality management systems.
• Technological Advancements: Development of more efficient and environmentally friendly manufacturing processes could provide competitive advantages.
• Emerging Markets: Growth in developing countries presents opportunities for suppliers, though price sensitivity may be higher.
• Shift to Combination Therapies: While formoterol fumarate is also used as a monotherapy, the trend towards fixed-dose combinations with inhaled corticosteroids (ICS) means API suppliers must be prepared to supply for these complex formulations.

What are the key challenges faced by formoterol fumarate API manufacturers?

Manufacturers of formoterol fumarate API face several challenges:

• Intense Price Competition: The generic nature of the market leads to significant pressure on pricing, impacting profit margins.
• Stringent Regulatory Compliance: Maintaining compliance with evolving global regulatory standards is costly and resource-intensive. Any lapse can lead to market access restrictions.
• Supply Chain Disruptions: Global events, geopolitical instability, and raw material sourcing issues can disrupt production and delivery.
• Environmental Regulations: Increasingly strict environmental regulations regarding chemical manufacturing processes require ongoing investment in cleaner technologies and waste management.
• Quality Control and Assurance: Ensuring consistent high quality and purity across large production volumes requires sophisticated quality control systems and experienced personnel.
• Intellectual Property Landscape: While molecule patents may be expired, navigating process and polymorph patents can still present complexities.

Key Takeaways

• The formoterol fumarate API market is dominated by manufacturers in China and India, with established players like Zhejiang NHU, Shandong Xinhua, Laurus Labs, and Divi's Laboratories holding significant market positions.
• Regulatory compliance, particularly GMP certification and robust DMF filings with agencies like the US FDA and EMA, is critical for market access.
• While core molecule patents have expired, process and polymorph patents can still influence the competitive landscape.
• Key quality attributes include high assay, strict impurity limits (related substances, residual solvents), controlled water content, and consistent physical characteristics such as particle size distribution.
• The market is characterized by intense price competition driven by genericization, necessitating economies of scale and efficient manufacturing processes.
• Future trends point towards continued regulatory scrutiny, potential market consolidation, and growth opportunities in emerging markets, alongside the increasing importance of supplying for fixed-dose combination products.

FAQs

1. What is the typical lead time for an order of formoterol fumarate API from a major supplier? Lead times can vary but generally range from 6 to 12 weeks for bulk orders, depending on the supplier's current production schedule, order volume, and required documentation.

2. Are there any specific API suppliers that hold exclusive or dominant patents on a particular formoterol fumarate polymorph? While the original formoterol fumarate molecule is off-patent, specific patents on advantageous polymorphs can exist. Companies like Chiesi Farmaceutici S.p.A. have historically been associated with innovations in formoterol fumarate formulations and related patents. However, API manufacturers typically focus on producing polymorphs that are either generic or licensed. Verification of current polymorph patent status for specific manufacturing routes is advised.

3. What is the difference in regulatory requirements for API suppliers targeting the US market versus the European market? Both the US (FDA) and Europe (EMA via national competent authorities) require GMP compliance. The primary difference lies in the submission format: US suppliers typically file a Drug Master File (DMF), while European suppliers file an Active Substance Master File (ASMF). Mutual Recognition Agreements (MRAs) between regulatory bodies can streamline inspections, but specific dossier requirements remain distinct.

4. How is the particle size distribution of formoterol fumarate API typically controlled and measured? Particle size distribution is controlled through manufacturing processes such as micronization (e.g., jet milling) and crystallization parameters. Measurement is commonly performed using techniques like laser diffraction. Key parameters like D10, D50, and D90 values are reported to ensure suitability for inhalation device compatibility.

5. What are the primary raw materials used in the synthesis of formoterol fumarate? The synthesis of formoterol fumarate typically involves multiple steps. Key precursor chemicals can include derivatives of salicylamide and alkylamines, along with various reagents and solvents such as formic acid, acetaldehyde, and isopropyl alcohol. Specific routes vary by manufacturer.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDA Submissions—Submitting Manufacturing Process Information. Retrieved from [FDA Website] (Specific URL may vary based on current guidance publication).

[2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from [EMA Website] (Specific URL may vary based on current guidance publication).

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from [ICH Website] (Specific URL may vary based on current guidance publication).

[4] Various Company Websites and Annual Reports (e.g., Zhejiang NHU Company Ltd., Laurus Labs Limited, Divi's Laboratories Limited, Aurobindo Pharma Limited, Shandong Xinhua Pharmaceutical Co., Ltd.). (Information accessed periodically).

[5] Global Pharmaceutical Market Reports and Industry Analyses (e.g., from IQVIA, EvaluatePharma, Grand View Research). (Publicly available summary data and trends).